TGTX Overview
Upcoming Projects (TGTX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (TGTX)
-
A Second Opinion: Analyzing the Phase 3b ENHANCE Study Results for Ublituximab (BRIUMVI) in Relapsing Forms of Multiple Sclerosis (RMS) from TG Therapeutics (TGTX)
Ticker: TGTX
Executed On: Dec 12, 2024 at 04:00 PM EST -
Analyzing the Phase 3b ENHANCE Study Results for Ublituximab (BRIUMVI) in Relapsing Forms of Multiple Sclerosis (RMS) from TG Therapeutics (TGTX)
Ticker: TGTX
Executed On: Dec 11, 2024 at 10:00 AM EST -
TGTX Briumvi Multiple Sclerosis Survey October 2024
Ticker: TGTX
Executed On: Oct 29, 2024 at 04:27 PM EDT -
Getting a prescriber's perspective comparing Briumvi, Ocrevus and Kesimpta in treating multiple sclerosis
Tickers: TGTX, RHHBY, NVS
Executed On: Oct 03, 2023 at 06:00 PM EDT -
Two Week Delay Survey: Assessing and Usage of TGTX's Briumvi and other ANTI-CD20 Drugs
Ticker: TGTX
Executed On: Aug 31, 2023 at 11:45 AM EDT -
A Second View: Discussing the potential of CD20 as class in treating Multiple Sclerosis with a focus on BRIUMVI, Kesimpta, and Ocrevus
Tickers: TGTX, NVS, RHHBY
Executed On: May 12, 2023 at 05:00 PM EDT -
Discussing the potential of CD20 as class in treating Multiple Sclerosis with a focus on BRIUMVI, Kesimpta, and Ocrevus
Tickers: TGTX, NVS, RHHBY
Executed On: May 11, 2023 at 02:30 PM EDT
Expired Projects (TGTX)
-
Discussing TGTX's Umbralisib UNITY-NHL Trial In wake of Rolling NDA Submission in Marginal Zone Lymphoma/Follicular Lymphoma
Tickers: TGTX, BMY, BAYN.XFRA
Execute By: Apr 03, 2020
Upcoming & Overdue Catalysts (TGTX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (TGTX)
-
TG Therapeutics (TGTX) withdraws BLA and sNDA for chronic lymphocytic leukemia, pulls Ukoniq from sale
Ticker: TGTX
Occurred on: Apr 15, 2022 -
IPI-549 Combination Dose-Escalation Expected to Complete 2H 2017
Ticker: TGTX
Occurred on: Jan 08, 2018 -
Interim Data from Phase 2b of UNITY-DLBCL expected 2H 2017
Ticker: TGTX
Occurred on: Aug 10, 2017 -
UNITY-CLL interim analysis of single agent arms expected 2H 2017
Ticker: TGTX
Occurred on: May 23, 2017 -
Data from Phase 2 MS trial expected to be presented at a major medical meeting in the first half of 2017
Ticker: TGTX
Occurred on: Apr 28, 2017 -
Phase 3 top-line data of TG-1101 (Ublituximab) and Imbruvica (GENUINE trial) for Chronic Lymphocytic Leukemia due first half 2017
Ticker: TGTX
Occurred on: Mar 06, 2017 -
TG Therapeutics (TGTX) Completes Enrollment for Part 1 of Phase 2 Study of TG-1101 in Relapsing Forms of Multiple Sclerosis (RMS)
Ticker: TGTX
Occurred on: Jan 11, 2017 -
TG Therapeutics (TGTX) Announces Positive DSMB Recommendation for Continuation of the UNITY-CLL Phase 3 Trial
Ticker: TGTX
Occurred on: Nov 22, 2016
Strategic Initiatives (TGTX)
-
TG Therapeutics (TGTX) and Novimmune Announce Global Agreement for Development and Commercialization of a Novel Anti-CD47/ Anti-CD19 Bispecific Antibody
Ticker: TGTX
Announcement Date: Jun 20, 2018
